The Vaccine Adjuvant market size is projected to grow from US$ 2,482.39 million in 2022 to US$ 6,931.55 million by 2030; the market is estimated to record a CAGR of 13.7% during 2022–2030. Technological advancements is likely to remain key trends in the market.
In 2020, NIAID established Vaccine Adjuvant Compendium (VAC) for the collaboration between broader scientific community and NIAID-supported vaccine adjuvant researchers. This network-based tool displays adjuvant characteristics to assist vaccine makers to identify suitable adjuvants for target disease. Also, support various government authorities to foster vaccine adjuvant R&D, top manufacturers collaborations, and product launches through such business strategies are likely to provide profitable opportunities for the growth of the vaccine adjuvants market during the forecast period.
Vaccine Adjuvant Technology encompasses nanotechnology, and its production includes supercritical, critical, or near-critical fluids with or without polar cosolvents such as ethanol [referred to as superfluids (SFS)]. Biodegradable biopolymers are dissolved in SFS and mixed with subunit vaccines in an aqueous solution or as a slurry of nanoparticles. Therefore, such new vaccine adjuvant technologies are being developed to make biodegradable polymer nanospheres (PNS) through novel processes, which allows vaccine manufacturers to rule out the use of organic solvents.
In recent years, adjuvant vaccines have been developed to enhance humoral and cell-mediated immune response after vaccination. By adding adjuvant components, vaccine efficacy is improved. The primary mechanisms of actions of the newer adjuvants involve enhancement of the innate immune system and lead to improved humoral and cell-mediated immunity against infections in populations.
Over past decades, non-biogenic adjuvants, biogenic adjuvants, and their multi-type of composite adjuvant materials studies are increasing, aiming at providing a theoretical basis for developing feasible and effective adjuvants for oral vaccines. With increasing studies related to vaccine adjuvants, strategic initiative are also happening in the market. For instance, In August 2023, Bimervax, the COVID-19 vaccine developed by the HIPRA Human Health, received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA). Bimervax is part of the SARS-CoV-2 virus spike protein combined with an adjuvant acting as an additional ingredient designed to trigger a strong immune response. It can also be administered as a booster shot in the upper arm, particularly for those aged 16 years and over. Such approvals for vaccine adjuvants is likely to favor the market growth from 2020 to 2030.
Key segments that contributed to the derivation of the vaccine adjuvants market analysis are adjuvant class and type.
The geographic scope of the Vaccine Adjuvants market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America has dominated the market and Asia Pacific is anticipated to grow with the highest CAGR in the coming years. Rising infectious disease and pandemics contribute to accelerating vaccine adjuvant production in Asia Pacific, influencing market growth during 2022-2030. In India, there is high support from the National Institute of Health (NIH), which contributes to the production of vaccines. One such example is the adjuvant developed by NIH funding to enhance the efficacy of India's COVAXIN Alhydroxiquim-II vaccine. The adjuvant used in COVAXIN, named “Alhydroxiquim-II”, was discovered and tested in the laboratory by ViroVax LLC, by incorporating a small molecule attached to “Alhydrogel”, a substance commonly known as alum standing as the most common adjuvant used in the vaccines for people.
The regional trends and factors influencing the Vaccine Adjuvants Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Vaccine Adjuvants Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 2,482.39 Million |
| Market Size by 2030 | US$ 6,931.55 Million |
| Global CAGR (2022 - 2030) | 13.7% |
| Historical Data | 2020-2021 |
| Forecast period | 2022-2030 |
| Segments Covered |
By Adjuvant Class
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Vaccine Adjuvants Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Vaccine Adjuvants Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The vaccine adjuvants market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the vaccine adjuvants market are listed below:
The “Vaccine Adjuvants Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:
The market is expected to register a CAGR of 14.0% during 2023–2031
The vaccine adjuvants market size is projected to reach US$ 7.96 billion by 2031.
Technological advancements is likely to remain key trends in the market
Advantageous and product approvals of veterinary vaccine adjuvants are the key driving factors behind the market development.
North America has dominated the vaccine adjuvants market
![](data:image/svg+xml;charset=utf-8,<svg height="60px" width="170px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="500px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="320px" width="500px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)